| General Information | |
|---|---|
| ZINC ID | ZINC000049785647 |
| Molecular Weight (Da) | 522 |
| SMILES | CN/C(=NS(=O)(=O)c1cccc(Cl)c1)C1=NN(c2ccc(Cl)cc2Cl)[C@@H](c2ccccc2)C1 |
| Molecular Formula | C23Cl3N4O2S1 |
| Action | Antagonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 132.966 |
| HBA | 4 |
| HBD | 0 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 33 |
| LogP | 6.304 |
| Activity (Ki) in nM | 331.131 |
| Polar Surface Area (PSA) | 82.51 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | + |
| Cyp2c9 inhibition | + |
| Cyp2c19 inhibition | - |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | - |
| Acute oral toxicity | + |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 1.201 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 18 |
| Fraction csp3 | 0.13 |
| Ilogp | 3.79 |
| Xlogp3 | 6.04 |
| Wlogp | 5.96 |
| Mlogp | 5.03 |
| Silicos-it log p | 5.22 |
| Consensus log p | 5.21 |
| Esol log s | -6.89 |
| Esol solubility (mg/ml) | 0.0000675 |
| Esol solubility (mol/l) | 0.00000012 |
| Esol class | Poorly sol |
| Ali log s | -7.55 |
| Ali solubility (mg/ml) | 0.0000147 |
| Ali solubility (mol/l) | 2.81E-08 |
| Ali class | Poorly sol |
| Silicos-it logsw | -9.5 |
| Silicos-it solubility (mg/ml) | 0.00000016 |
| Silicos-it solubility (mol/l) | 3.15E-10 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -5.19 |
| Lipinski number of violations | 2 |
| Ghose number of violations | 3 |
| Veber number of violations | 0 |
| Egan number of violations | 1 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.17 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 2 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 4.36 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -5.451 |
| Logd | 2.427 |
| Logp | 5.431 |
| F (20%) | 0.001 |
| F (30%) | 0.001 |
| Mdck | 1.53E-05 |
| Ppb | 0.9948 |
| Vdss | 0.569 |
| Fu | 0.0178 |
| Cyp1a2-inh | 0.594 |
| Cyp1a2-sub | 0.657 |
| Cyp2c19-inh | 0.95 |
| Cyp2c19-sub | 0.91 |
| Cl | 0.452 |
| T12 | 0.026 |
| H-ht | 0.817 |
| Dili | 0.99 |
| Roa | 0.383 |
| Fdamdd | 0.977 |
| Skinsen | 0.064 |
| Ec | 0.003 |
| Ei | 0.007 |
| Respiratory | 0.872 |
| Bcf | 1.181 |
| Igc50 | 5.049 |
| Lc50 | 5.824 |
| Lc50dm | 4.825 |
| Nr-ar | 0.008 |
| Nr-ar-lbd | 0.089 |
| Nr-ahr | 0.417 |
| Nr-aromatase | 0.053 |
| Nr-er | 0.232 |
| Nr-er-lbd | 0.005 |
| Nr-ppar-gamma | 0.168 |
| Sr-are | 0.604 |
| Sr-atad5 | 0.005 |
| Sr-hse | 0.009 |
| Sr-mmp | 0.93 |
| Sr-p53 | 0.517 |
| Vol | 468.847 |
| Dense | 1.109 |
| Flex | 0.231 |
| Nstereo | 1 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 1 |
| Surechembl | 0 |
| Nonbiodegradable | 1 |
| Skin sensitization | 1 |
| Acute aquatic toxicity | 1 |
| Toxicophores | 2 |
| Qed | 0.332 |
| Synth | 3.129 |
| Fsp3 | 0.13 |
| Mce-18 | 78.846 |
| Natural product-likeness | -1.387 |
| Alarm nmr | 2 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | 1 |
| Gsk | Rejected |
| Goldentriangle | Rejected |